A Neuropharmacological Critique of Cannabis-Induced Cerebral Hypoperfusion Diagnosed
Confounding Factors in Methodology, Toxicology, and Neuroadaptation
Abstract
The clinical utilization of Single-Photon Emission Computed Tomography (SPECT) by practitioners like Dr. Daniel Amen to diagnose cannabis-induced cerebral hypoperfusion has generated significant public debate. Amen’s observations suggest that hypoperfusion, notably in the right hippocampus, serves as a predictive marker separating cannabis users from controls and implies “deleterious brain effects” linked to neurodegenerative pathology.[1] This paper asserts that interpreting SPECT-derived hypoperfusion as definitive evidence of cannabis neurotoxicity is methodologically flawed and scientifically premature. The core issues stem from three primary failures: (1) the inherent methodological limitations of SPECT, including restricted resolution and poor temporal dating; (2) the systematic neglect of critical confounding variables, specifically the highly variable pharmacokinetics governed by the route of administration (inhalation versus oral) and the profound toxicological risks associated with heavy metal and pesticide contamination in industrial cannabis products; and (3) a misinterpretation of functional changes, failing to recognize that perfusion anomalies may represent a dynamic, adaptive, and homeostatic response of the endocannabinoid system (ECS). This critique integrates molecular pharmacology, toxicology, and advanced neuroimaging modalities, concluding that a precise assessment of cannabis risk requires moving beyond simplistic, anatomically focused perfusion maps to incorporate multimodal imaging and a nuanced understanding of the ECS’s role as a major regulatory and healing system.
I. Introduction
1.1. The Specter of Hypoperfusion: Dr. Amen’s Clinical Claims
The introduction of cannabis into broader medical and recreational markets has amplified the need for rigorous neuroscientific assessment of its long-term effects. Dr. Daniel Amen’s clinic has notably utilized SPECT imaging to visualize cerebral blood flow patterns in individuals reporting psychiatric symptoms and substance use.[2] His findings report widespread “low perfusion” or hypoperfusion across multiple brain regions in cannabis users.[1] Specific findings, such as right hippocampal hypoperfusion, have been highlighted as the most predictive marker distinguishing cannabis users from healthy controls, leading to the public conclusion that cannabis use carries significant, deleterious brain effects and raises the possibility of pathologies akin to Alzheimer’s disease,[1] now known as type III diabetes of which unprocessed trauma is a contributing factor. These interpretations often frame regulated substances, including cannabis, as being comparable in danger to long-established legal drugs such as nicotine and alcohol.[2]
1.2. The Scientific Challenge: Causality, Confound, and Context
While regional hypoperfusion is a relevant biological signal, robust science requires establishing a clear, mechanism-based causal link, a task complicated by the heterogeneity of cannabis products, modes of consumption, and user demographics. The central challenge to Amen’s observations is the lack of experimental control over critical variables essential for isolating the effect of the plant’s intrinsic compounds (cannabinoids) from the method of their delivery or the presence of exogenous contaminants. Therefore, a comprehensive critique must assess the methodological robustness of SPECT and contextualize the observed perfusion changes within the modern understanding of neuropharmacology and the homeostatic function of the ECS.
Thesis Statement: The widespread interpretation of SPECT-derived hypoperfusion as definitive evidence of cannabis neurotoxicity is methodologically unsound, primarily due to the limitations of SPECT resolution, the failure to control for critical confounding variables—specifically route-of-administration pharmacokinetics and inhalation-related toxicological exposure—and a fundamental misinterpretation of the endocannabinoid system (ECS) neuroadaptation. A comprehensive analysis integrating molecular biology (ECS advancements over the last 20 years) and advanced neuroimaging modalities (QEEG, ASL-MRI) is required to accurately contextualize the risk profile of cannabis use.
II. Methodological Critique: The Limits of SPECT in Assessing Cannabis Effects
2.1. Diagnostic Resolution and Temporal Limitations of SPECT
Single-Photon Emission Computed Tomography (SPECT) measures cerebral blood flow (CBF) and perfusion, providing a functional map of brain activity. However, when applied to dynamic and subtle psychiatric conditions, the inherent technical limitations of SPECT significantly restrict the interpretability of its findings. The clinical use of SPECT is restricted by its limited resolution.[3]
Contemporary neuroimaging modalities often provide superior resolution and data utility. For instance, perfusion/arterial spin labeling (ASL) MRI is advantageous because it does not use ionizing radiation, relying instead on magnetically labeled endogenous blood water, resulting in a minimally invasive procedure.[3] While ASL-MRI is limited by low temporal resolution and a low signal-to-noise ratio [3], its avoidance of radiation offers a key advantage over SPECT.[3] Furthermore, Quantitative Electroencephalography (QEEG) provides an alternative that does not require radiation, is low-cost (around $600), and records neuronal activity with very high temporal resolution, though it is constrained to measuring brain wave activity at the scalp and offers limited information regarding subcortical structures.[3, 4] The necessity for high temporal resolution is critical when examining the effects of a rapidly acting substance like inhaled cannabis.
A critical vulnerability in the SPECT methodology, particularly for chronic substance use studies, lies in its inability to establish temporal causality. A common limitation of SPECT is that clinicians rarely have a prior, or baseline, imaging study for comparison.[3, 5] This absence means it is often not possible to date a trauma or insult using neuroimaging.[3] Functional imaging findings of brain trauma, which SPECT is effective at detecting, often show similarities between remote trauma that occurred in childhood and more recent trauma.[3, 5] Since the hypoperfusion observed in cannabis users is the most predictive region distinguishing them from controls [1], the inability to differentiate historical, unrelated insults (e.g., prior concussions, which patients may fail to report [3], or pre-existing cardiovascular issues Dr. Amen acknowledges [2]) from cannabis-induced changes compromises the ability to assign causality definitively to recent drug use.
2.2. The Paradigm Gap: Clinical Training and Diagnostic Interpretation
The clinical paradigm employed by Dr. Amen emphasizes observable, anatomically focused deficits, particularly perfusion anomalies, as singular markers of psychiatric illness.[2] This focus is characteristic of older neurobiological models, raising questions about whether his diagnostic interpretation incorporates modern advancements in functional and molecular neurobiology, particularly those detailed in contemporary dissertation research (O’Brien, 2023a).
Modern neurobiology views mental health through the lens of dynamic, inter-network connectivity, neuroplasticity, and sophisticated homeostatic regulation mechanisms, prominently featuring the endocannabinoid system (ECS) (Section V). A clinical framework relying solely on a static, low-resolution blood flow map risks a reductive simplification where complex functional states are misinterpreted as irreversible structural damage. The SPECT methodology, therefore, risks over-attributing causality based on anatomical perfusion deficits without accounting for the dynamic, adaptive nature of the brain—a concept that has flourished in the last two decades.
III. Confounding Variables: Pharmacokinetics and Delivery Route
The claim that negative observations are the result of the plant itself, and not the potency or route of administration, ignores critical pharmacological principles. The route of administration dictates the speed and magnitude of Δ9-tetrahydrocannabinol (THC) delivery, which is arguably the single most important determinant of acute CNS and cardiovascular effects.
3.1. The Critical Role of Inhalation vs. Oral Administration
The pharmacokinetics of cannabinoids vary drastically depending on how they enter the body. Inhalation (smoking or vaporization) avoids the extensive first-pass metabolism that occurs in the liver following oral administration.[6] This metabolic process typically breaks THC down into 11-OH-THC, a psychoactive metabolite that contributes to overall pharmacological activity.[6]
| Route of Administration | Bioavailability (Mean Range) | Time to Peak Plasma THC (Tmax) | Metabolic Profile | Acute CNS Impact Profile |
| Inhalation (Smoking/Vaping) | High (11% to 45%; mean 31%) [7] | Rapid (0–10 minutes) [6] | Avoids extensive first-pass metabolism [6] | High potential for acute hemodynamic stress |
| Oral (Edibles/Capsules) | Low (≈6% in humans) [7] | Slow (0–4 hours) [8] | Extensive first-pass metabolism [6] | Reduced acute central vascular impact |
Oral delivery results in a much lower bioavailability (≈6% in humans) [7] and leads to significantly lower peak THC plasma concentrations (Cmax) compared to inhaled routes, even when administered in similar doses.[8, 9]
3.2. Hypoperfusion as an Acute Hemodynamic Artifact
The profound difference in Cmax between inhaled and oral routes provides a powerful explanation for observed hypoperfusion that bypasses the hypothesis of intrinsic neurotoxicity. High, rapid THC delivery via inhalation is known to induce systemic and cerebral vasoconstriction. The hypoperfusion visualized on a SPECT scan could therefore be an acute, physiological, and hemodynamic response to a high-concentration drug bolus, rather than evidence of permanent structural destruction.
The differential physiological effects based on the route of administration are substantiated by research demonstrating that the inhaled (flower) group experienced a higher heart rate post-use than the edible group, confirming that physiological responses diverge significantly based on how rapidly the drug reaches the systemic circulation.[9] If hypoperfusion is a marker of long-term structural damage caused by cannabinoids, then oral users should exhibit a similar, albeit delayed or milder, signal due to the presence of psychoactive metabolites. The failure to conduct controlled comparisons means that the hyper-acute effects associated with the inhalation delivery system are conflated with the drug’s intrinsic properties. This methodological oversight prevents the conclusion that the negative observations are not simply a function of the delivery route.
3.3. Lack of Controlled Comparison Groups
The question of whether Dr. Amen’s work includes a comparison study between non-users, inhaled users, and oral-only users remains unanswered by the public domain. The scientific literature often compares chronic heavy smokers to non-smoking controls, identifying altered functional activity in various regions such as the anterior cingulate cortex, prefrontal cortex, and striatum.[10, 11] However, these studies do not isolate the route of administration to the high-fidelity required to decouple cannabinoid effects from inhalation-specific effects.
The critical comparison group—individuals who consume cannabis exclusively via oral routes—provides a “clean” pharmacological test, minimizing the rapid Cmax delivery and avoiding the combustion-related byproducts inherent in smoking. The absence of this control group in Dr. Amen’s data means that any attribution of the SPECT findings to cannabis rather than smoked cannabis is inconclusive.
IV. Toxicological Confound: Heavy Metal and Pesticide Neurotoxicity
A second, and often ignored, confounding variable in SPECT-detected hypoperfusion among inhaled cannabis users is the profound risk of toxicological exposure through heavy metals and pesticides. Dr. Amen’s observations are compromised by the failure to rule out contaminants used on cannabis farming.
4.1. Cannabis as a Phytoremediator and Contaminant Accumulation
The Cannabis plant possesses unique characteristics as a phytoextractor, capable of accumulating and concentrating heavy metals (HMs) from the soil.[12, 13] Historically, this capability has been used for environmental cleanup, such as absorbing toxic HMs and dioxin from contaminated areas.[12] When cannabis is grown in areas with a history of mining or unregulated agriculture, it scavenges HMs like lead (up to 30 mg/kg of dry material) and cadmium (up to 14.8 mg/kg).[13] These toxins are absorbed and travel up the stalk into the leaves and flowers, which are then smoked or vaporized.[12]
Studies have confirmed that people who smoke marijuana have higher levels of toxic heavy metals in their blood and urine compared with non-users, including 27% higher levels of lead and 22% higher levels of cadmium in their blood.[12] Furthermore, inhaled marijuana smoke contains not only HMs like cadmium (Cd), cobalt (Co), nickel (Ni), and zinc (Zn) but also potentially pesticides.[13]
4.2. Neurotoxic Mechanisms of Contaminants and Potential Link to Hypoperfusion
The contaminants in inhaled cannabis are potent neurotoxins that exert effects independent of THC. Heavy metal exposure is a significant risk factor for neurological disorders, operating through mechanisms such as the generation of reactive oxygen species, mitochondrial dysfunction, and the activation of inflammatory pathways.[14] Glial cells (microglia and astrocytes) are highly susceptible to metal-induced neurotoxicity, promoting microglial activation that leads to neuroinflammation, alteration in synaptic transmission, and neuronal damage.[14]
Specifically, cadmium is a Group 1 human carcinogen that induces proinflammatory cytokines and is linked to the progression of Alzheimer’s and Parkinson’s disease.[13] Exposure to cadmium is associated with decreased attention and memory impairments in humans.[13] The oxidative stress and neuroinflammation caused by HMs are known precursors to cerebrovascular compromise. SPECT technology has precedent in assessing regional cerebral blood flow changes in neurotoxicity induced by heavy metals, such as mercury.[15]
Consequently, the hypoperfusion detected in the hippocampus [1], a region highly vulnerable to oxidative stress and Alzheimer’s pathology (which HMs are known to accelerate), may be a physical manifestation of neuroinflammation and cerebrovascular insult caused by chronic toxic exposure, misattributed to the cannabis plant’s active compounds. Since Dr. Amen’s clinical observations do not account for stringent toxicological screening, the failure to rule out pesticides and heavy metals means the SPECT findings are severely compromised by environmental toxicology.
V. Neuroplasticity, Homeostasis, and Brain Development
A fundamental limitation of interpreting hypoperfusion as evidence of neurotoxicity is the failure to distinguish between pathological destruction and functional, adaptive neuroplasticity.
5.1. The Endocannabinoid System’s Developmental and Protective Role
The endocannabinoid signaling system (ECS) is not merely a mechanism for intoxication; it is a critical, complex regulatory system involved in human life from the onset of embryogenesis.[16] The ECS controls key developmental processes, including neurogenesis, neuronal migration, morphological guidance for neuronal connectivity, and synaptic circuitry refinement.[16]
Crucially, the ECS performs a pro-homeostatic and neuroprotective function in both acute and chronic pathologies of the central nervous system, including neurodegenerative diseases such as multiple sclerosis, Huntington’s, Parkinson’s, and Alzheimer’s.[17] This protective mechanism is mediated through the activation of CB1 and CB2 receptors.[17] While it is accepted that exposure to exogenous cannabinoids during specific windows of vulnerability, such as adolescence, impacts neurodevelopment by changing dendritic structure and synaptic functions [16, 18], the changes observed are part of a regulatory feedback loop.
5.2. Interpreting Functional Changes: Adaptation, Not Destruction
The functional and metabolic changes observed via neuroimaging often represent the brain’s dynamic compensatory efforts to maintain stability. Functional MRI (fMRI) research supports this concept: while acute THC intoxication causes hypoactivation in occasional users, sober chronic cannabis users demonstrate hyperactivation in the mesocorticolimbic circuit.[19]
This shift is explained by neuroadaptation, specifically the fluctuation in CB1 receptor density, which is a known neuroadaptive response deployed by the brain to regain homeostasis following sustained CB1 agonist exposure (THC).[19, 20] Therefore, the hypoperfusion observed by SPECT [1] may not indicate destruction but rather the brain’s attempt to restore equilibrium. The SPECT findings are potentially capturing the metabolic signature of this adaptive process, such as compensatory receptor downregulation to stabilize neurotransmission. The question of whether the increased impact on brain development is providing something necessary over being destructive must therefore be framed by the system’s homeostatic imperative. The observed hypoperfusion is potentially the metabolic manifestation of the brain attempting to restore stability, an adaptive change that is fundamentally different from permanent pathology.
VI. Integrating EEG Data: The Question of Alpha Waves
6.1. Cannabis and Resting-State EEG Spectral Power
To accurately assess the brain’s functional state, high-temporal resolution techniques are necessary. When addressing the query of whether cannabis increases alpha waves in the brain, the electrophysiological literature provides a consistent affirmation. Research hypothesized and confirmed that cannabis users exhibit changes in spectral power compared to controls, specifically showing increased power in the theta and alpha bands.[21] These findings include greater coherence in the frontal regions and increased clustering coefficient in the frontal regions across the delta, theta, and alpha bands.[21]
Increased alpha power is generally correlated with relaxation and internalized conscious states, whereas beta activity indexes cortical excitation.[22] The disruptive effect of marijuana smoking on the task difficulty effect in the alpha band further confirms that cannabinoids actively alter this specific pattern of cortical synchronization.[23]
6.2. Decoupling of Metabolism and Function
The concurrent finding of reduced cerebral perfusion (hypoperfusion) via SPECT [1] alongside evidence of increased, organized functional activity (increased alpha coherence) via EEG suggests a dissociation between metabolic demand and functional outcome. If the hypoperfused tissue were truly pathologically destroyed, it would be unlikely to exhibit coordinated, increased frequency band activity.
Instead, this combination suggests that cannabinoid exposure drives a shift in brain state characterized by a metabolic efficiency or lower energy resource utilization (hypoperfusion) but with a simultaneous, organized shift in functional activity (increased alpha coherence). This decoupling supports the neuroadaptive hypothesis: the brain is functionally altering its state and metabolic requirements to accommodate the cannabinoid challenge, confirming that the change is a dynamic shift in processing rather than a catastrophic functional failure.
VII. Modern Molecular Neuroscience: The Healing ECS and 20 Years of Advancement
The scientific foundation available to a medical doctor practicing 50 years ago, or those relying exclusively on dated neuroimaging paradigms, significantly limits the capacity to qualify and quantify the endocannabinoid system as a major part of the body’s healing mechanism and to account for all the medical advancements over the last 20 years.
7.1. The ECS as a Major Regulatory and Healing System
The ECS is now recognized as a ubiquitous, central regulatory system. Endocannabinoids, such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), function primarily as retrograde messengers.[24] They are produced in the postsynaptic neuron and travel backward across the synapse to bind to presynaptic CB1 receptors, signaling the suppression of neurotransmitter release, thereby regulating crucial signaling molecules like glutamate, GABA, and glycine.[24]
Furthermore, the CB2 receptor is a key component of the ECS’s protective role. While CB2 receptors are primarily expressed on immune cells, including microglia [25], their activation is generally anti-inflammatory [25] and central to the pro-homeostatic and neuroprotective functions observed in neurodegenerative and neuroinflammatory diseases.[17]
7.2. Molecular and Pharmacological Breakthroughs (Post-2000)
The last two decades have brought fundamental changes to cannabinoid pharmacology, moving toward precision targeting that explicitly seeks to unlock the ECS’s therapeutic potential while mitigating the acute effects that SPECT likely detects. Key advancements include:
1. Structural and Genetic Foundation: The successful crystal structure determination of CB1-R and CB2-R, confirming them as seven-transmembrane G-protein coupled receptors (GPCRs), has provided the structural foundation necessary for rational drug design and the development of subtype-selective ligands.[24]
2. Targeting Endogenous Tone: A core strategic shift has been to move away from direct global CB1 agonist activation (which causes psychoactive effects and potential systemic side effects like perfusion changes) to enhancing endogenous endocannabinoid tone. This is achieved through inhibiting the degradation enzymes—Fatty Acid Amide Hydrolase (FAAH) and Monoacylglycerol Lipase (MAGL).[24] This approach ensures that endocannabinoid levels are elevated locally, providing an auto-protective and more selective homeostatic role in pathologies like inflammation and neurodegeneration.[24]
3. Allosteric Modulation (PAMs and NAMs): Modulators that bind to allosteric sites—distinct from the orthosteric binding site—allow for highly refined control over receptor signaling.
◦ Positive Allosteric Modulators (PAMs): Compounds such as GAT229 (a pure CB1-R PAM) and EC21a (the first synthetic CB2-R PAM) enhance the effect of orthosteric agonists without inducing effects on their own.[24] This strategy is promising for neurodegenerative disorders, enhancing therapeutic efficacy with minimized side effects.[24]
◦ Negative Allosteric Modulators (NAMs): NAMs, such as ORG27569, weaken the impact of orthosteric ligands. Structural analysis confirmed that NAMs bind to an extrahelical site, causing the agonist-binding pocket to adopt an inactive conformation.[24]
4. Functional Selectivity (Biased Signaling): Biased agonists (e.g., PNR-4-20) selectively activate either the G protein or the β-arrestin pathway.[24] This advancement is critical because G-protein signaling often mediates desired therapeutic effects, whereas β-arrestin recruitment is typically associated with receptor internalization and long-term desensitization, allowing researchers to refine therapeutic outcomes.[24]
5. Targeted Delivery Systems: Advances in nanotechnology, including the design of optimized nanocarriers and surface modification techniques, are used to improve drug delivery specificity and overcome formulation challenges associated with cannabinoids.[24]
This explosion of molecular knowledge over the last two decades demonstrates that the scientific community views the ECS as a vital and precise therapeutic target. The side effects that SPECT-based observations emphasize (e.g., acute CB1 activation leading to perfusion changes) are precisely the problems that modern pharmacology is specifically designed to bypass through selective modulation and targeted delivery. Therefore, any interpretation of cannabis effects that fails to incorporate the context of these targeted strategies and the ECS’s central homeostatic role provides an obsolete and unbalanced assessment.
VIII. Conclusion and Recommendations
8.1. Synthesis of Nuanced Conclusions
Dr. Amen’s SPECT-based observations of cerebral hypoperfusion in cannabis users are highly susceptible to severe methodological, pharmacokinetic, and toxicological confounding factors, preventing the establishment of a clear causal link between cannabinoid exposure and irreversible neurological destruction.
The critique demonstrates three fundamental flaws in the interpretation:
1. Methodological Limitation: SPECT’s low spatial and temporal resolution, along with its inability to date the onset of perfusion anomalies, makes it inadequate for distinguishing between remote, unrelated insults (e.g., head trauma) and recent cannabis effects.[3, 5]
2. Uncontrolled Confounding Variables: The interpretation fails to account for the route-dependent pharmacokinetics, where inhaled use results in high, rapid Cmax delivery of THC likely inducing a transient, hemodynamic vasoconstriction mistaken for chronic pathology.[6, 9] Furthermore, the lack of toxicological control means that the hypoperfusion signal could be a manifestation of neuroinflammation and cerebrovascular insult caused by heavy metal and pesticide contamination inherent in non-regulated cannabis, independent of the cannabinoids themselves.[12, 13]
3. Misinterpretation of Neuroadaptation: Viewing hypoperfusion as inevitable destruction ignores the sophisticated homeostatic and neuroprotective capacity of the ECS.[17] The observed functional changes, which occur concurrently with EEG evidence of increased alpha power (suggesting an organized shift in functional state) [21, 22], are more accurately characterized as dynamic neuroadaptive mechanisms designed to restore equilibrium following sustained agonist exposure.[19]
The complexity of the ECS, exemplified by the profound advancements in targeted pharmacology (e.g., allosteric modulators, biased agonists, and enzyme inhibitors) over the last 20 years [24], confirms that the system is leveraged for healing and precision therapeutics, rendering a generalized, destructive interpretation of crude cannabis effects scientifically obsolete.
8.2. Future Research Directives
To advance the accurate scientific understanding of cannabis risk and therapeutic potential, future neurobiological research must adhere to a higher standard of methodological rigor:
1. Mandatory Multimodal Neuroimaging: Studies must utilize a combination of perfusion analysis (SPECT or ASL-MRI) with high-temporal resolution functional mapping (QEEG).[3] This approach is essential to decouple metabolic rate (perfusion) from functional brain states (electrical activity), providing a complete picture of neuroadaptation. (See our example HERE)
2. Controlled Pharmacokinetic Studies: Future clinical investigations must rigorously control for and compare non-users, inhaled users, and oral-only users.[10] This design is the only means to isolate the effects of the cannabinoid molecule itself from the deleterious effects associated with the inhalation delivery route.
3. Stringent Toxicological Screening: All cannabis material used in clinical research must undergo comprehensive toxicological screening for heavy metals (lead, cadmium) and pesticides to eliminate these significant environmental confounds.[12, 13]
4. Integration of Molecular Markers: Neuroimaging findings must be correlated with molecular and genetic markers of neuroadaptation, such as CB1 receptor density or enzyme expression, to confirm whether observed changes reflect pathology or adaptive neuroplasticity.[19]
5. Modernizing Clinical Education: Clinicians should be mandated to incorporate the molecular advancements of the last two decades regarding the ECS—including the mechanisms of allosteric modulation and functional selectivity—to contextualize the risks of crude cannabis within the vast, targeted therapeutic potential of the system.[24]
——————————————————————————–
1. Discriminative Properties of Hippocampal Hypoperfusion in …, https://pubmed.ncbi.nlm.nih.gov/27886010/
2. Cannabis: The Heart and Brain Risks No One Warned You About – Amen Clinics, https://www.amenclinics.com/cannabis-the-heart-and-brain-risks-no-one-warned-you-about/
3. Brain SPECT Imaging in Complex Psychiatric Cases: An Evidence-Based, Underutilized Tool – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC3149839/
4. Brain Imaging: SPECT, fMRI, & QEEG and what they uncover in the brain – neurocare group, https://www.neurocaregroup.com/news-insights/brain-imaging-what-they-uncover
5. A New Way Forward: How Brain SPECT Imaging Can Improve Outcomes and Transform Mental Health Care Into Brain Health Care – Frontiers, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.715315/full
6. Clinical Evaluation of the Cannabis-Using Patient: A Moving Target, https://www.thepermanentejournal.org/doi/10.7812/TPP/24.088
7. Mechanisms of Action and Pharmacokinetics of Cannabis – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC8803256/
8. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans – Frontiers, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01365/full
9. A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC12238766/
10. Altered Affective Response in Marijuana Smokers: An FMRI Study – PMC – PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC2752701/
11. Neuroimaging meta-analysis of cannabis use studies reveals convergent functional alterations in brain regions supporting cognitive control and reward processing – PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC5858977/
12. HEALTH ALERT: Marijuana Users Have Higher Levels of Toxic Heavy Metals, https://everybrainmatters.org/2023/10/03/marijuana-users-have-higher-levels-of-toxic-heavy-metals/
13. Marijuana Toxicity: Heavy Metal Exposure … – Semantic Scholar, https://pdfs.semanticscholar.org/43d5/9fa627af64deff06e8954ed44aed3055c9ab.pdf
14. Glial Perturbation in Metal Neurotoxicity: Implications for Brain Disorders – MDPI, https://www.mdpi.com/2571-6980/6/1/4
15. A quantitative evaluation of brain dysfunction and body-burden of toxic metals – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC3560777/
16. Cannabis, Endocannabinoids and Brain Development: From Embryogenesis to Adolescence – MDPI, https://www.mdpi.com/2073-4409/13/22/1875
17. The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases – Brieflands, https://brieflands.com/journals/ijhrba/articles/19578
18. Cannabis in Adolescence: Lasting Cognitive Alterations and Underlying Mechanisms – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9940816/
19. Cannabis Use and Neuroadaptation: A Call for Δ9-Tetrahydrocannabinol Challenge Studies, https://pmc.ncbi.nlm.nih.gov/articles/PMC9046729/
20. A Systematic Review of Human Neuroimaging Evidence of Memory-Related Functional Alterations Associated with Cannabis Use Complemented with Preclinical and Human Evidence of Memory Performance Alterations – PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC7071506/
21. Cannabis users exhibit increased cortical activation during resting state compared to non-users – PMC – PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC6693493/
22. Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC8857346/
23. Effects of marijuana on neurophysiological signals of working and episodic memory – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC1463999/
24. Recent Advances in Endocannabinoid System Targeting for …, https://pmc.ncbi.nlm.nih.gov/articles/PMC9658826/
25. Review of the Endocannabinoid System – PMC – PubMed Central – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC7855189/
